美国急性缺血性卒中干预的种族、社会经济与地理差异
该研究基于2016-2018年美国全国住院患者样本,回顾性分析成人缺血性卒中患者接受静脉阿替普酶(tPA)和血管内取栓(EVT)的比例及差异。结果显示tPA使用从8.8%增至10.2%,EVT从2.8%增至4.9%,但黑人、低收入和农村患者接受干预的 odds 显著更低。
要点
- 2016-2018年美国缺血性卒中患者tPA使用率从8.8%升至10.2%,EVT从2.8%升至4.9%。
- 黑人患者接受tPA的OR为0.82,EVT的OR为0.75,均低于白人患者。
- 低收入(≤$37,999)患者tPA的OR为0.81,EVT的OR为0.84,均低于高收入(>$64,000)患者。
核心结论
- 2016-2018年美国缺血性卒中患者tPA和EVT使用率均上升,但种族、社会经济和地理差异持续存在。
研究设计与样本
- 回顾性纵向分析2016-2018年美国全国住院患者样本,纳入成人缺血性卒中患者,加权后队列共1,439,295例。
主要发现
- tPA使用比例从2016年8.8%增至2018年10.2%(p<0.001),EVT从2.8%增至4.9%(p<0.001)。
- 黑人 vs 白人:tPA的OR为0.82(95%CI 0.79-0.86),EVT的OR为0.75(95%CI 0.70-0.81)。
- 邮政编码中位收入≤$37,999 vs >$64,000:tPA的OR为0.81(95%CI 0.78-0.85),EVT的OR为0.84(95%CI 0.77-0.91)。
- 农村 vs 大都市:tPA的OR为0.48(95%CI 0.44-0.52),EVT的OR为0.92(95%CI 0.81-1.05)。
- 调整NIHSS后上述关联大多维持,但效应大小有所变化;性别与tPA或EVT无一致关联。
关键数值与推荐
- 黑人患者接受tPA的OR为0.82(95%CI 0.79-0.86),EVT的OR为0.75(95%CI 0.70-0.81)。
- 低收入(≤$37,999)患者tPA的OR为0.81(95%CI 0.78-0.85),EVT的OR为0.84(95%CI 0.77-0.91)。
- 农村患者tPA的OR为0.48(95%CI 0.44-0.52),EVT的OR为0.92(95%CI 0.81-1.05)。
临床怎么用
- 临床应关注黑人、低收入和农村缺血性卒中患者,识别并减少tPA和EVT使用中的差异。
- 针对农村患者tPA使用率显著偏低,需优化院前转运和卒中中心覆盖。
局限性
- 回顾性分析基于行政数据库,可能存在编码偏倚和未测量混杂因素。
- 部分患者缺乏基线NIHSS评分,限制了对卒中严重程度的充分调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In patients with ischemic stroke (IS), IV alteplase (tissue plasminogen activator [tPA]) and endovascular thrombectomy (EVT) reduce long-term disability, but their utilization has not been fully optimized. Prior research has also demonstrated disparities in the use of tPA and EVT specific to sex, race/ethnicity, socioeconomic status, and geographic location. We sought to determine the utilization of tPA and EVT in the United States from 2016-2018 and if disparities in utilization persist. METHODS: This is a retrospective, longitudinal analysis of the 2016-2018 National Inpatient Sample. We included adult patients who had a primary discharge diagnosis of IS. The primary study outcomes were the proportions who received tPA or EVT. We fit a multivariate logistic regression model to our outcomes in the full cohort and also in the subset of patients who had an available baseline National Institutes of Health Stroke Scale (NIHSS) score. RESULTS: The full cohort after weighting included 1,439,295 patients with IS. The proportion who received tPA increased from 8.8% in 2016 to 10.2% in 2018 (p < 0.001) and who had EVT from 2.8% in 2016 to 4.9% in 2018 (p < 0.001). Comparing Black to White patients, the odds ratio (OR) of receiving tPA was 0.82 (95% confidence interval [CI] 0.79-0.86) and for having EVT was 0.75 (95% CI 0.70-0.81). Comparing patients with a median income in their zip code of ≤$37,999 to >$64,000, the OR of receiving tPA was 0.81 (95% CI 0.78-0.85) and for having EVT was 0.84 (95% CI 0.77-0.91). Comparing patients living in a rural area to a large metro area, the OR of receiving tPA was 0.48 (95% CI 0.44-0.52) and for having EVT was 0.92 (95% CI 0.81-1.05). These associations were largely maintained after adjustment for NIHSS, although the effect size changed for many of them. Contrary to prior reports with older datasets, sex was not consistently associated with tPA or EVT. DISCUSSION: Utilization of tPA and EVT for IS in the United States increased from 2016 to 2018. There are racial, socioeconomic, and geographic disparities in the accessibility of tPA and EVT for patients with IS, with important public health implications that require further study.
引用
- de Havenon A, Sheth K, Johnston KC, et al. Acute Ischemic Stroke Interventions in the United States and Racial, Socioeconomic, and Geographic Disparities. Neurology. 2021. PMID: 34649872. doi:10.1212/WNL.0000000000012943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。